Clinical Trial Working Groups
|
|
- Open trial: Renal cell carcinoma (Illinois)
- Current concepts:
- Bladder (Iowa)
- Bladder (Michigan)
- Bladder (Penn State)
- Next call: Friday, August 7
at 10 a.m. ET / 9 a.m. CT
- Approved LOI: Esophageal (Indiana)
- Next call: Friday, September 11
at 1 p.m. ET / 12 p.m. CT
-
Trial in start-up: Hepatocellular (Indiana)
- Approved LOI: Esophageal (Indiana)
- Current concepts:
- Colorectal (Wisconsin)
- Hepatocellular (Wisconsin)
- Gastric/GE Junction Adenocarcinoma (Northwestern)
- Next call: Friday, August 28
at 3 p.m. ET / 2 p.m. CT
- Current concepts:
- First line triple negative metastatic breast cancer (Penn State)
- Newly diagnosed ER+, HER2- breast cancer (Minnesota)
- Next call: Tuesday, August 11
at 4 p.m. ET / 3 p.m. CT
- Approved LOI: Endometrial carcinoma (Northwestern)
- Next call: Friday, September 4
at 2 p.m. ET / 1 p.m. CT.
- Current concept: Squamous cell carcinoma of the skin (Rutgers)
- Next call: Thursday, July 30
at 1 p.m. ET / 12 p.m. CT
- Current concepts (not yet presented):
- Peripheral T-cell lymphoma (3 concepts) (Michigan)
- Cutaneous T-cell lymphoma (Michigan)
- Lymphoma (Minnesota)
- Next call: Wednesday, July 22
at 11 a.m. ET / 10 a.m. CT (joint call with Multiple Myeloma group)
- Current concept: Acute myeloid leukemia (Indiana)
- Next call: Tuesday, August 11
at 1 p.m. ET / 12 p.m. CT
- Current concept: Multiple myeloma (Indiana)
- Next call: Wednesday, July 22 at 11 a.m. ET / 12 p.m. CT (joint call with Lymphoid group)
Join a CTWG: Contact Donna LaPlaca Sullivan at
[email protected] or 317-634-5842, ext. 40.
|
|
|
|
Opportunities for Faculty
|
The Big Ten Cancer Research Consortium (BTCRC) was established in 2013 to provide new opportunities for collaborative, investigator-initiated research at Big Ten cancer centers. Faculty have been actively involved throughout the consortium's development, resulting in the achievement of many milestones. The BTCRC opened its first clinical trial recently, and numerous other trials and concepts are in the pipeline.
The BTCRC brings together exceptional basic scientists and clinical investigators within the Big Ten Conference to collaborate on the next generation of genomically driven, multi-institutional clinical trials. Through the consortium's shared resources and large patient base, BTCRC studies will be completed efficiently, speeding the development of new therapies for patients.
The BTCRC welcomes the participation of all faculty at member institutions, including junior and senior level basic scientists and clinical investigators. Faculty are encouraged to take the following steps to engage with their consortium colleagues:
Join a BTCRC clinical trial working group (CTWG).
The working groups provide a collaborative environment in which to discuss clinical trial concepts and advise the protocol development process. The following CTWGs meet via teleconference every 6 to 8 weeks.
Bring your clinical trial concepts to the BTCRC.
To submit a concept, contact Jessica Roy, the BTCRC's research development director, at [email protected].
|
Learn how the Masonic Cancer Center is investing in the resources and talent needed to address the needs of personalized cancer therapy, in this Q&A with Douglas Yee, MD, director, and Jeffrey Miller, MD, deputy director, of Masonic Cancer Center, University of Minnesota, our featured member for July. Read more.
To see past member features, click here. |
This month, we draw attention to significant milestones and achievements at BTCRC member institutions: From the launch of the consortium's first clinical trial at the University of Illinois, to Dr. Max Wicha's appointment to the National Cancer Advisory Board by President Obama; from significant funding to BTCRC institutions by the Howard Hughes Medical Institute and the American Cancer Society, to the University of Nebraska's partnership with IBM on the Watson Genomic Analytics program. We celebrate the groundbreaking of the Michigan State University Grand Rapids Research Center, and we highlight advances in research Across the Consortium. Read more.
|
|
|